Table 1 Clinical and pathological baseline of validation and training cohort

Gender(male/female)

39(60.9%)/25(39.1%)

54(56.3%)/42(43.8%)

0.347

0.556

Age,years

66.2 ± 8.9

62.1 ± 10.6

2.488

0.014

Bismuth-Corlette classification(I/II/IIIA/IIIB/IV)

8(12.5%)/6(9.4%)/15(23.4%)/19(29.7%)/16(25.0%)

8(8.3%)/16(16.7%)/16(16.7%)/23(24.0%)/33(34.4%)

4.642

0.326

CEA level, ng/ml(≤ 5/>5)

47(73.4%)/17(26.6%)

69(71.9%)/27(28.1%)

0.047

0.828

CA19-9 level, U/mL(≤ 559.8/>559.8)

47(73.4%)/17(26.6%)

61(63.5%)/35(36.5%)

1.714

0.190

DB level, umol/l (≤ 8/>8)

9(14.1%)/55(85.9%)

24(25.0%)/72(75.0%)

2.806

0.094

TB level,umol/l (≤ 34/>34)

11(17.2%)/53(82.8%)

23/(24.0%)/73(76.0%)

1.052

0.305

Tumor diameter, cm

2.9 ± 1.3

3.3 ± 1.6

1.707

0.090

Biliary calculi(no/yes)

48(75.0%)/16(25.0%)

77(80.2%)/19(19.8%)

0.610

0.435

Pathological differentiation(poor/moderate/well)

27(42.2%)/32(50.0%)/5(7.8%)

36(37.5%)/52(54.2%)/8(8.3%)

0.354

0.838

cN stage(0/N1/N2)

37(57.8%)/22(34.4%)/5(7.8%)

46(47.9%)/40(41.7%)/10(10.4%)

1.530

0.465

Number of lymph node dissection(< 7/≥7)

28(43.8%)/36(56.3%)

32(33.3%)/64(66.7%)

1.778

0.182

AJCC T stage (T1-2 / T3-4)

29(45.3%)/35(54.7%)

32(33.3%)/64(66.7%)

2.336

0.126

Resection margins(R0/R1)

58(90.6%)/6(9.4%)

76(79.2%)/20(20.8%)

3.705

0.054